Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).
1 finding from 1 review
Total adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
total adverse events in "healthy" persons · "healthy" old persons and demented women
procaine may leads to higher total adverse events in "healthy" persons compared with placebo (low certainty).
1 finding from 1 review
Total number of people with adverse events, · people with acute ischemic stroke
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).
1 finding from 1 review
Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Serious adverse events by total adverse events · patients with upper gastrointestinal bleeding and liver diseases.
Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with ankylosing spondylitis
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total number of serious adverse events not measured · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Adverse effects: 1. General ‐ overall number of events · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ general ‐ total general adverse events ( compared with placebo (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ nervous system disorders ‐ total nervous system… compared with placebo (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ gastrointestinal disorders ‐ total gastrointestinal… compared with placebo (low certainty).
1 finding from 1 review
Study author‐reported adverse events · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
It is very uncertain whether omega‐3 fatty acids and antioxidants changes total number of adverse events (study author reported anytime during… compared with placebo or standard nutrition (very low certainty).
1 finding from 1 review
Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD
Cipaglucosidase plus miglustat showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa plus placebo (low certainty).
1 finding from 1 review
Adverse events: 2. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA SHRS total · people with psychosis
1 finding from 1 review